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INTRODUCTION 
In Estelle v. Gamble1, the United States Supreme Court recognized that "[a ]n inmate 
must rely on prison authorities to treat his medical needs; if the authorities fail to do so, 
those needs will not be met." The Court held that the State has a constitutional obligation 
under the Eighth and Fourteenth Amendments to provide adequate medical care to those 
whom it has incarcerated.2 However, Estelle did not set forth exactly what qualifies as 
"adequate" medical care. Does this mean that the State must supply the latest standard 
of medical care? This paper will address the seriousness of Hepatitis C if left untreated; 
the current standard of medical care provided for the treatment of Hepatitis C, which 
has a cure rate of ninety percent; and whether or not the State is required to supply 
that treatment to prison inmates to satisfy the constitutional obligations of providing 
adequate medical care. 
Today courts are reviewing class action lawsuits that have been filed by prison inmates 
seeking the current standard of medical care for their Hepatitis C. 3 In reaching a ruling, 
the courts will need to determine whether the Department of Corrections is required 
to provide inmates the new standard of care for the treatment of Hepatitis C, which 
is a very costly drug. This new wave of drugs for the treatment of Hepatitis C can 
cost anywhere from $89,000 to a discounted rate of $40,000 per inmate, which could 
potentially undermine the budgets of the Department of Corrections nationwide.4 
This article will first briefly set forth a general background of Hepatitis C, including 
what it is, how it is diagnosed and treated. Part II of this article will explain the current 
standard of medical care and the treatment developments. Part III of this article will 
address whether or not the Department of Corrections should be constitutionally 
required to treat all inmates currently diagnosed with Hepatitis C with the latest 
developed drugs, based off of three pending class action lawsuits brought by prisoners 
against the state Department of Corrections. Part IV of this article will discuss possible 
policy implications by examining the Wyoming Department of Corrections Policies, 
and finally this article will conclude by finding that absent a diagnosis of an advanced 
stage of Hepatitis C, the states' Department of Corrections should not be mandated to 
provide this costly treatment to inmates. 
1 Estelle v. Gamble, 429 U.S. 97, 103 (1976) 
care from the corrections aep1art1ner11) 
that inmate did not receive proper medical 
2 Id. at l 04. See also v. Williamson, 191N.C.487, 490 (1926). 
3 See Chimenti v. Dept. of Corrections, No. 15-3333, 2016 U.S. Dist. LEXIS 36682 
(E.D. Pa. Mar. 21, 2015); Paszko v. O'Brien, No. l-15-cv-12298-NMG (D. Mass. June 10, 2015); 
v. Minnesota Dept. of Corrections, No. 15-cv-02210-PJS-BRT (D. Minn. filed May l, 2015). 
4 SAM PK. COLLINS, Prisoners in lvlassachusetts 
PROGRESS (June 16, 2015), httT1'"/ith1nlCT1rnDTle" 
treatments to be at rates of 90% or more). 
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I. BACKGROUND 
A. What is Hepatitis C? 
First, it is important to understand what Hepatitis C is and how it affects the body. 
Hepatitis C is the most common chronic blood-borne infection in the United States with 
about 4 million people diagnosed with chronic Hepatitis C.5 This disease is caused by 
a virus that infects and inflames the liver.6 For some people the infection lasts only a 
short time, and the body is able to clear the virus.7 However, most people infected with 
Hepatitis C develop chronic Hepatitis C.8 Chronic Hepatitis C is a long-term illness that 
happens when the virus stays in the body.9 The majority of people who have chronic 
Hepatitis C are not even aware that they carry the disease because symptoms often 
do not develop for many years until the infection has started to damage their liver. 10 
According to the Center for Disease Control and Prevention (CDC), nearly eight in ten 
untreated people will remain infected for life. 11 CDC provides annual reports that break 
down the number of people infected into age groups. 12 
The largest category of those infected fall into the baby boomer era (those born from 
1946 to 1964 ). 13 The CDC states that this may be due to these people becoming 
infected before the virus was identified and blood was tested for the disease. 14 
According to the United States Census Bureau, there are currently 76.4 million baby 
boomers living in the United States, 15 which increases the importance of testing 
individuals in this category. 16 The CDC has even stated that baby boomers are five 
times more likely to have Hepatitis C. 17 Additionally, the CDC reports that there has 
been a steady increase in the number of cases reported since 2009, at least through 
5 FDA Consumer Updates, Faster, Easier Hepatitis C, http://>vww.fda.gov/ForConsumers/ 
ConsmnerUpdates/ucm405642.htm (last visited Nov. 13, 2015). 
6 Id. 
7 Nat'! Ctr. for Biotechnology Info., US. Nat'] of Med., Hepatitis C, http://ww·vv.ncbi.nlm. 
nih.gov/pubmedhealth/PMHT0022399/ visited Sept 12, 2015)[hereinafter NIH Hepatitis Cl 
s Id. 
9 Nat'l Ctr for Biotechnology Info., US. Nat'! Library of Med., Chronic Hepatitis, 
nlmnih.gov/pubmedhealth/PMHT0023081/ visited Sept 15, 2015). 
w Id. 
11 Id. (causing those people to chronic Hepatitis C). 
12 See, e.g, Center for Disease Control and Prevention, United 
States, 2013, http://www.cdc.gov/hepatitis/statistics/2013 surveillance/ commentary.htm#hepatitisC 
(last visited Sept l 0, 2015) [hereinafter CDC Surveillance]. 
t3 Id. 
14 Id 
15 Kelvin Pollard & Paila Scommegna, POPULATION REFERENCE BuREAU, Just How 
Boomers Are There, http://wwvv.prb.org/Publications/A1iicles/2002/ 
JustHowManyBabyBoomersAreThere.aspx visited Sept 15, 2015). 
16 Center for Disease Control and Prevention, C, Saves Lives, 
(May 2013) (noting that many baby boomers became 
infected before the dangers of Hepatitis C were well knov\111). 
17 ld. 
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the 2013 reports. 18 Moreover, in 2013, forty-one states reported an estimate of 
29, 718 cases of acute Hepatitis C across the United States. 19 
If Hepatitis C is left untreated, over time (up to twenty years or longer in some people) 
the infection could damage the liver.20 Untreated Hepatitis C could also cause cirrhosis 
(scarring of the liver that makes the liver not function correctly), liver cancer, liver 
failure, and potentially even death.21 Hepatitis C is a leading cause of liver cancer and 
the most common reason for liver transplants in the United States.22 Recent studies 
reflect about 15,000 deaths in the United States each year are due to Hepatitis C.23 
B. How is Hepatitis C Transmitted? 
Hepatitis C is an infectious and contagious liver disease that spreads through blood-
to-blood contact with an infected person. 24 Hepatitis C may be spread by sharing 
razors, toothbrushes, needles, syringes or other equipment that is used to inject 
drugs. 25 Individuals may also be put at risk simply by getting a tattoo with unsterilized 
tools, receiving a blood transfusion prior to 1992, or even being born to a mother 
infected with Hepatitis C. 26 Other occupational hazards may present risks to exposure, 
especially in the medical and dental fields. 27 Finally, adults that are incarcerated in 
correctional facilities are at risk because many inmates already have Hepatitis C. 28 It 
can be difficult to eliminate exposure because bleaching, boiling, heating with a flame, 
18 See CDC Surveillance, supra note 12. 
19 Id. (The CDC's National Notifiable Disease Surveillance System (NNDSS), viral hepatitis case-
reports are received electronically from state health departments via CDC's National Electronic 
Telecommnnications System for Surveillance (NETSS), a computerized public health surveillance 
system that provides the CDC with data regarding cases on a weekly basis. Although surveillance 
infrastructure is in place, reports are not submitted by all states. As noted in a recent report from 
the Institute of Medicine (Institute of Medicine, Hepatitis and liver cancer: a national strategy 
for prevention and control B and C. Washington, DC: The National Academies Press, 
2010: 1-232. ), surveillance capacity to monitor viral hepatitis is limited at the state and local levels, 
resulting in underreporting. To account for under-ascertainment and under-reporting, an estimation 
method was developed in 2011 to better quantify the number of new cases of hepatitis A, B, and C 
from the actual number of cases reported for each disease. (Klevens RM, Liu SJ, Roberts H, Jiles 
RB, Holmberg SD. Estimating acute viral hepatitis infections from nationally reported cases. Am J 
Public Health. 2014;104(3):482-7).) 




24 U.S. DEP'T OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION, 
HEPATITIS c AND INCARCERATION (Oct. 2013), http://~rww.cdc.gov/hepatitis/HCV/PDFs/ 




28 Id. (stating that eliminating Hepatitis C exposure is difficult in general, but especially so in 
prisons with high volume of infected persons). 
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or using a common cleaning fluid (such as alcohol or peroxide) is not strong enough 
to kill the virus. 29 
The CDC breaks down the 2013 reported risk exposure and behavior cases and their 
transmission into the following groups: (1) 61.6% indicated use of injection drugs; 
(2) 16.4% of males indicated sex with another male; (3) 18.4% reported sexual 
contact with a person confirmed or suspected to have Hepatitis C; 30 ( 4) 1 % reported 
occupational exposures, including employment in a medical, dental, or another field 
involving contact with human blood; (5) 12.2% indicated having surgery; and (6) 
7.7% indicated having an accidental needle stick or puncture.31 This breakdown is 
only derived from reported cases.32 
Most people do not notice any symptoms of Hepatitis C for many years until the 
virus begins to damage their liver.33 When symptoms of Hepatitis C do appear, they 
often appear as symptoms caused by common illnesses and go undiagnosed until they 
manifest as liver damage.34 These symptoms include: fever, upset stomach and nausea, 
diarrhea, loss of appetite, feeling exhausted, yellowed eyes and skin called "jaundice", 
swelling of the belly, easy bruising, and taking longer for bleeding to stop.35 
C. Information on Testing for Hepatitis C 
According to the CDC, the only way to know if someone has Hepatitis C is to get 
tested. Doctors use a blood test, called a Hepatitis C Antibody Test, which will identify 
antibodies to the virus and reveal if a person has ever been infected with Hepatitis C.36 
Antibodies are chemicals released into the bloodstream when someone gets infected.37 
Test results may take anywhere from a few days to a few weeks to come back, and can 
either produce a non-reactive or negative result (meaning that a person does not have 
Hepatitis C, or that they have not been infected for a period long enough to be detected) 
or a reactive/positive result (meaning that antibodies were found in the blood).38A 
reactive antibody test does not necessarily mean a person still has Hepatitis C.39 Once 
a person has been infected, they will always have antibodies in their blood, even if they 
29 See HEPATITIS c AND INCARCERATION, supra note 24. 
30 See CDC Surveillance, supra note 12, at 4.6a. 
31 Id. 
Id. 
33 See NlH C, note 7. 
Id. 
35 Robin Madell, Reviewed 
8, 2016, What Are the Symptoms and Warning Signs C?, nrtjJ:lrW"Ww.11ea.1m1me. 
AND lNCARCERAf!ON, supra note 24. 
36 Hepatitis C and Baby Boomers 




visited on Jan. 30, 2017); See qer1en11Lv 
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have cleared the Hepatitis C virus.40 A reactive antibody test requires an additional, 
follow-up test to determine if a person is currently infected with Hepatitis C.41 
D. The Prevalence of Hepatitis C in Correctional Facilities 
A significant number of people who enter the prisons and jails are already suffering 
from serious health conditions.42 The correctional system becomes responsible for 
an inmate's health care and treatment during incarceration.43 It is pertinent to note 
the difference between jails and prisons to better understand the duration that an 
inmate may be under the care and control of the facility.44 Because there is a rapid 
turnover within the incarcerated population, the funding for correctional health and 
prevention services often limits the correctional system in providing both curative and 
preventative care.45 
According to the CDC, in 2013, there were 2.2 million people in the United States jails 
and prisons, and one in three had Hepatitis C.46 However, a 2014 report indicates that 
the rate of infected inmates "declined to 17.4%"47, with those diagnosed with chronic 
infection "estimated to be between 12 and 35%."48 The inmate population diagnosed 
with Hepatitis C represents about one-third of the total cases in the United States.49 
The CDC notes that Hepatitis C poses a serious health problem for those incarcerated, 
because many inmates already have the virus, and Hepatitis C is the most common 
type of hepatitis in jails and prisons.50 Accordingly, the CDC recommends universal 
40 Id. (See also IVLwo CLINIC, IVLwo MEDICAL LABORATORIES, Test ID: HCVL, Hepatitis C 
Virus Antibody Confirmation, Serum, http://v1l\¥W.mayomedicallaboratories.com/test-catalog/ 
Overview/63063, (last visited on Jan. 30, 2017). 
41 Id. 
42 NATIONAL RESEARCH COUNCIL OF THE NATIONAL ACADEMIES, The Growth in the 
United States: Exploring Causes and Consequences, Chapter 9, Pg. 221 (2014). https://wv</\v.nap. 
edu/read/18613/chapter/9#22 l 
43 Id. 
44 See Management of Hepatitis C in Jails versus Prisons, CENTER FOR DISEASE CONTROL AND 
PREVENTION (Jan. 4, 2017), http://wVl!\V.hepatitisc.uw.edu/pdf/special-populations-situa1ions/ 
treatment-corrections/core-concept/all (noting that a person is jailed upon arrest for allegedly 
committing a crime. Most states will hold individuals in jail for sentences up to 1 year, although this 
may be extended to include longer sentences. Jails are typically operated and funded by local cities 
or counties, whereas prisons are part of either a state or federal system, and house persons convicted 
of felonies.) 
4s Id. 
46 See HEPATITIS c AND INCARCERATION, supra note 24. 
47 Varan et al.Hepatitis C SeroprevalenceAmong Prison Imnates Since 2001: Still High but 
Declining. Public Health Reports, 2014; 129: 187-195 
49 Id. (citing Varan et al.Hepatitis C SeroprevalenceAmong Prison Inmates Since 2001: Still High 
but Declining. Public Health Reports, 2014; 129: 187-195.). 
so Id. 
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Hepatitis C screening for all incarcerated inmates. 51 The National Hepatitis Corrections 
Network states that high prevalence of Hepatitis C within the prison system may 
also be attributable to the populations who are most affected by incarceration (such 
as the poor, injection drug users, and the mentally ill), who are more likely to have 
Hepatitis C52 . The most common ways inmates transmit Hepatitis C include sharing 
equipment used for injecting drugs, tattooing and piercing with those individuals that 
are already infected with the virus.53 Since correctional health facilities pose a high 
risk for contracting the virus, the CDC recommends counseling and testing to prevent 
spreading the infection.54 
II. STANDARD OF MEDICAL CARE 
A. Treatment Options for Hepatitis C 
Due to recent medical developments, if a person today is diagnosed with Hepatitis C, 
it no longer means months and months of painful drug injections, which was the only 
treatment option available for decades.55 Science is continually developing new means 
and methods for treating all medical diseases and illnesses, the treatment for Hepatitis 
C is no different.56 In fact, science has made leaps and bounds in the development for a 
cure.57 The first "curing" oral treatment regimen (Sovaldi) was approved by the FDA late 
in December, 2013.58 Today, there are even more mediations that have been approved 
by the FDA to treat the various genotypes of Hepatitis C, and have been proven to have 
successful cure rates.59 
51 Management of Hepatitis C in Jails versus Prisons, http://www.hepatitisc.uw.edu/pdf/special-
populations-situations/treatment-corrections/core-concept/all 
52 Nat's Hetatitis Corrections Netrowk, An Overview of Hepatitis C in Prisons and Jails, 
(0212212016), http://www.hcvinprison.org/resources/7 l -main-content/ content/ 191-hepcprison 
53 Id 
54 See generally CENTERS FOR DISEASE CONTROL AND PREVENTION, US. DEP'T OF HEALTH AND HuMAN 
SERVICES, MMWR No. 47RR-19, RECOMMENDATIONS FOR PREVENTION AND CONTROL OF HEPATITIS C 
VIRUS (HCV) INFECTION AND HCV-RELATED CHRONIC DISEASE, (1998), https://www.cdc.gov/mmwr/ 
preview/mmwrhtml/00055154.htm. 
55 See FDA Consumer Updates, supra note 5. 
56 See generally Anne Harding, Pros and Cons of New Hepatitis C Drugs, EVERYDAY HEALTH, http:// 
www.everydayhealth.com/news/pros-cons-new-hepatitis-treatments-patients/ (page last updated: 
April 7, 2015); American Liver Foundation, Advances in Medication to Treat Hepatitis C, (October 
2016), http://hepc.liverfoundation.org/treatment/the-basics-about-hepatitis-c-treatment/advances-in-
medications/ 
57 American Liver Foundation, Can hepatitis C Be Cured?, (October 2016), (The Hepatitis C virus 
is considered cured if the virus is not detected in your blood 3 months after treatment is completed) 
58 Id (Sovaldi (sofosbuvir)), a once-daily pill, was approved to treat HCV genotypes 1, 2, 3 and 4. 
This was the first drug that allowed genotype 2 and 3 patients to be treated with pills only, offering 
an interferon-free regimen with ribavirin. 
59 American Liver Foundation, Advances in Medication to Treat Hepatitis C, (October 2016), 
http ://hepc. liverfoundation. mg/treatment/the-basics-about -hepatitis-c-treatment/ advances-in-
medications/ (Harvoni, which is a once-daily pill that combined sofosbuvir (Sovaldi) and a new drug 
called ledipasvir was approved in October, 2014; In November, 2014, the FDA granted simeprevir 
(Olysio) an additional approval to be used in combination ¥.':ith sofosbuvir (Solvaldi) as a once-daily, 
all-oral, interferon and ribavirin-free treatment for adults with genotype 1 HCV infection. This 
33 
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Prior to 2013, Interferon-based injections were the only option for treatment. 60 Interferon 
was approved in the 1990s, and when later combined with Ribavirin (another drug that 
fights the virus) the cure rate jumped from less than 5% in the 1980s to about 50% by 
the early 2000s.61 
However, Interferon and Ribavirin cause many side effects including muscle aches, 
fever, nausea, anxiety, and trouble sleeping.62 These medications often need to be taken 
for forty-eight weeks to see results, and in some instances have required taking the 
regimen for up to a year without results.63 
In 2011, the United States Food and Drug Administration (FDA) approved two new 
drugs: boceprevir (Victrelis) and telaprevir (Incivek), which stop the virus from 
making a copy of itself. 64 Combining telaprevir or boceprevir with interferon and 
ribavirin pushed success rates as high as 70%.65 However, the drug combination still 
was not ideal; as the additional drugs increased so did the side effects.66 In 2013 and 
2014, the FDA approved three new drugs: (1) Simeprevir (Olysio), (2) Sofosbuvir 
(Sovaldi), and (3) Ledipasvir-sofosbuvir (Harvoni). 67 The combination of Simeprevir 
with interferon and ribavirin clears the Hepatitis C virus in up to 80% of people who 
take it. 68 According to the FDA, Ledipasvir-sofosbuvir can be taken without interferon 
and ribavirin. 69 Sofosbuvir can also be used without interferon for people with some 
approval gave people with genotype 1 another all-oral treatment option; December, 2014, the FDA 
approved a new combination medicine called Viekira Pak ( ombitasvir/paritaprevir/ritonavir tablets; 
dasabuvir tablets), which can be given with or without Ribavirin, to treat adults with genotype 1 
infection; then in July, 2015, the FDA approved two new drugs - Technivie for the treatment of 
genotype 4 and Daklinza for the treatment of genotype 3. Further developments were approved in 
2016, with Zapatier ((elbasvir 50 mg/grazoprevir 100 mg) being approved in January to treat adults 
with chronic HCV genotypes 1 or 4 infection, including those with compensated cirrhosis, HIV-1 
co-infection, or severe kidney disease and on dialysis, and most recently in June, 2016, Epclusa 
(sofosbuvir 400mg/velpatasvir 100 mg) which is a new combination medicine, was approved to treat 
genotypes 1, 2, 3, 4, 5, or 6. It is also the first single tablet regimen approved for the treatment of 
patients with HCV genotype 2 and 3, without the need for ribavirin.) (October, 2016). 
60 See FDA Consumer Updates, supra note 5. See also American Liver Foundation, Advances in 
Medication to Treat Hepatitis C, (October 2016), http://hepc.liverfoundation.org/treatment/the-
basics-about-hepatitis-c-treatment/advances-in-medications/ (last visited Feb. 8, 2017) 
61 U.S. Dept. of Veterans Affairs, Interferon and Ribavarin Treatment Side Effects, TOPIC REVIEW, 
http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp (page last updated: Aug. 26, 
2016). 
62 Id. 
63 U.S. Dep't ofVeteranAffairs, Hepatitis C Genotypes and Quasispecies, TOPIC REVIEW (2005), 
http://www.hepatitis.va.gov/provider/reviews/genotypes.asp. 
64 Alan Francisus, A Brief History of Hepatitis C, 4.3 HCV Advocate 1, 5-6 (2015), http:// 
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types of Hepatitis C. 70 Sofosbuvir, which seems to be the most ideal choice for a cure, 
comes in an easy once-a-day pill. 71 It takes as few as twelve weeks to work, and has a 
cure rate of up to 90%.72 
In January 2014, the Infectious Disease Society of America and the American 
Association for the Study of Liver Disease issued guidelines recommending treatments 
by genotype, including prescribing sofosbuvir and similar drugs as the first line of 
therapy to replace Interferon injections entirely.73 The HCV Guidance has since been 
updated to reflect developments and FDA approvals as of July 6, 2016.74 Recent 
clinical trials with the breakthrough drugs (instead of interferon), have been found to 
have even higher rates of "virologic success" and fewer side effects,75 which should 
lead to even more widespread success. 76 
All of these new drugs allow a shorter treatment span without injections and produce a 
higher cure rate. 77 There is no wonder that many people diagnosed with the disease want 
to have access to them. This has recently prompted the filing of class action lawsuits from 
prison inmates alleging that they have been denied access to "adequate" medical care, in 
violation of their Constitutional rights under the Eighth and Fourteenth Amendments. 78 
B. Just What Does This Cure Cost? 
One can easily say that the new drugs are not cheap. The cost is a daunting $84,000 
for a 12-week course of Sofosbuvir, or approximately $1,000 per pill. 79 Even with 
this high price, prison providers are starting to use this next generation of agents, in 
certain instances. 80 
70 See Francisus, supra note 64. 
71 See American Liver Foundation, supra note 63 
72 Id. 
73 American Association for the Study of Liver Diseases and Infectious Diseases Society of 
America (AASLD), HCV Guidance: Recommendations for Test, Managing and Treating Hepatitis 
C, http://hcvguidelines.org/ (last visited Feb. 8, 2017). 
74 Id. See http://hcvguidelines.org/full-report/initial-treatment-box-sunuuary-recommendations-
patients-who-are-initiating-therapy-hcv for the latest recommendations for patients who are 
initiating therapy. 
75 See Kowdley et al., Lawitz E, Ledipasvir and Sofosbuvir for 8 or 12 chronic 
HCV without cirrhosis, 370(20) N Engl J Med. 1879 (2014), http://www.nejm.org/doi/pdf/10.1056/ 
NEJMoa1402355. 
76 See Feld et al., Treatment of HCV with ABT-450/Rombitasvir and Dasabuvir with Ribavirin. 370 
N Engl J Med. 1594 (2014), http://www.nejm.org/doi/pdf/10.1056/NEJMoal315722. 
77 See American Liver Foundation, supra note 63 
78 See Chimenti v. Pennsylvania Dept. of Corrections, No. 15-3333, 2016 U.S. Dist. LEXIS 36682 
(E.D. Pa. Mar. 21, 2015); Paszko v: O'Brien, No. 1-15-cv-12298-NMG (D. Mass. June 10, 2015); 
Ligons v. Minnesota Dept. of Corrections, No. 15-cv-02210-PJS-BRT (D. Minn. filed May 1, 2015). 
79 Charles Ornstein, New Hepatitis C Drugs are Costing lv!edicare Billions, THE WASH. PosT 
(March 29, 2015), https://W\vw.washingtonpost.com/national/health-science/medicare-spent-45-
billion-on-new-hepatitis-c-drugs-last-year-data-shows/20 l 5/03/29/66952dde-d3 2a-1 l e4-a62f-
ee74591 l a4ff_story.html. 
so Federal Bureau of Prisons, Interim Guidance for the _Management of Chronic Hepatitis C 
Infection, (2014 ), http://W\vw.bop.gov/resources/pdfs/hepatitis_c_current.pdf. 
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Other government-managed programs like Medicaid and Medicare are still working 
out the standards for people who want to take the new medications. 81 The Washington 
Post reported that Medicare spent over $4.5 billion dollars of federal taxpayer money 
on treating Hepatitis C alone, which included the elevated costs for the newly approved 
drugs. 82 Medicaid on the other hand was much more restrictive with providing the 
drugs, and often required the patients to have advanced liver disease to be eligible for 
the newly approved pills. 83 However, it is reported that Medicaid acknowledges that 
"anticipated legal challenges may compel state Medicaid programs to stop rationing 
the new drugs."84 As the prison systems are also publicly funded, the high cost of these 
drugs could have detrimental effects on Department budgets, in the event that they are 
required to pay for the treatment of all inmates85 . In fact, the new treatment options 
could costs six to eight times more than prescribing Interferon. 86 
Recent reports show that despite the high costs of treatment, some prison systems are 
offering the new drugs to inmates, 87 the most notable is the Federal Bureau of Prisons. 88 
However, the Federal Bureau of Prisons, which oversees the federal prison system, is 
reported to be receiving a 44% discount on the new drugs, enabling it to provide the 
treatment to inmates. 89 
C. How Will This Cure Affect Correctional Facilities? 
In order for the United States to effectively eliminate Hepatitis C, this would require 
providing treatment to prisoners. As described above, there is an overwhelming 
percentage of inmates who currently have Hepatitis C, and the cost of treating and 
curing this disease is expensive. At costs of approximately $84,000 per person, without 
81 Medicaid.gov, Keeping America Heathly, HCV Communication, https://www.medicaid.gov/ 




85 Peter Loftus and Gary Fields, High Cost C Drugs Strains Prison Locks 
Many Out The Wall Street Journal, September 12, 2016, https://www.wsj.com/articles/high-
cost-of-new-hepatilis-c-drugs-strains-prison-budgets-locks-many-out-of-cure-1473701644 
86 Ann Harding, Medically reviewed by Matthew Vosanger, MD, Pros and Cons of New Hepatitis 
C Drugs, Everyday Health, (April 7, 2015), hHp://wvvw.everydayhealth.com/news/pros-cons-new-
hepatitis-treatments-patients/ 
87 Dave Boucher, USA Today Network, The Tennessean, Gov. Bill Haslam 
Tennessee prison Hepatitis C request (Jan. 31, 2017), nm><11ww1AJ tE,nnesseai~.com/st11rv'/m,ws/ 
See also Anna 
Maria Barry-Jester, Prisoners with Hep C Get Cured in Some States But Not in Others (Oct. 13, 
https :/ /fivethirtyeight. com/features/prisoners-with-hep-c-get -cured-in-some-states-but -not -
others; See also CBS NEws, $1000-a-day Hepatitis C Drug Approved to Treat Prison lmnates in 
Illinois, (April 18, 2014), http:/ /vvww.cbsnews.com/news/l 000-a-day-hepatitis-c-drug-approved-to-
treat-prison-inmates-in-illinois/ 
88 See Federal Bureau of Prisons, supra note 80 at 1. 
89 Victoria Law, Hepatitis C is Common in Prison, but Treatment is Rare, Hepatitis C Serious 
but Curable, THE BODY, August 24, 2015, http://www.thebody.com/content/763271hepatitis-c-is-
common-in-prisons-but-treatment-is-.html (last visited Sept. 23, 2015). 
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any discount such as that which the Veterans Affairs or the Federal Bureau of Prisons 
is reported to receive - this cure would potentially undermine the Department of 
Corrections' budgets.90 Recent reports indicate that it would take an estimated $33 
billion dollars to treat all of the incarcerated people, which is more than four times the 
total health spending by state prison systems.91 
Although United States prisons offer routine screenings for HIV, not all prisons offer 
screenings for Hepatitis C, which may provide an explanation for the spreading of the 
virus within the prisons. The Federal Bureau of Prisons published an Interim Guidance 
for the Management of Chronic Hepatitis C Infection in June, 2014.92 This guideline 
specifically acknowledges the advancing treatments and rapidly changing clinical 
guidelines with the progression of science.93 The guideline sets forth a prioritized 
treatment plan beginning with those diagnosed with advanced stages of the virus and 
liver transplant recipients, then moving down the list to inmates that are also HIV co-
infected, and lastly to those newly incarcerated inmates who were being treated at the 
time of incarceration. 94 Perhaps the most on target issue can be found in the guideline 
outlining the recommended treatment regimens.95 Although the treatment is evaluated 
on a case-by-case basis, the "Preferred regimen" is the sofosbuvir + ribavirin 12-week 
program.96 The guideline also specifically categorizes treatment regimens that are no 
longer recommended, which includes Interferon, unless an inmate is completing a 
course of treatment that has already been started with Interferon.97 
Prisoners have a constitutional right to healthcare, even beyond that of the general 
population. 98 This right falls within the Eighth and Fourteenth Amendments, and 
requires the correctional facilities to provide adequate medical care. 99 Estelle v. 
Gamble established that the Eight Amendment "imposes duties on [prison] officials, 
who must ... ensure that inmates receive adequate ... medical care, and must 'take 
reasonable measures to guarantee the safety of the inmates."'100 
With the excessive costs of treatment, correctional facilities have yet to provide this 
treatment for all individuals diagnosed with the disease, but instead have tried to focus 
on those with advanced stages of the disease, and the duration an inmate will be in 
ErGm,August 2015, 
91 Id. 





97 See Federal Bureau of Prisons, note 80 3. 
98 Estelle v. Gamble, note at 103. 
99 
100 101-102. 
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custody. 101 Within the last year, class action lawsuits in three states have been filed 
to put pressure on the correctional facilities to provide these new drugs, which may 
provide a cure for Hepatitis C. These class actions were filed on behalf of prisoners 
in Minnesota, Pennsylvania and Massachusetts. 102 These suits were brought under the 
Eighth and Fourteenth Amendments under the United States Constitution, for which 
42 U.S.C. § 1983 provides declaratory, equitable and legal remedies. 103 The complaints 
also include allegations under Title II of the Americans with Disabilities Act as 
Amended and §504 of the Rehabilitation Act of 1973. 104 Jurisdiction is argued by the 
plaintiffs in those suits to be established under both a federal question and a federal 
civil rights question. 1 os 
The complaints filed in each of these three cases set out the same basic principles: (1) 
the prisoners suffer from serious medical need, disability and a life-threatening viral 
disease known as Hepatitis C, (2) the acknowledgement of the FDA "breakthrough" 
drugs twelve week daily-pill therapy protocol approved to cure Hepatitis Cat a 95% rate 
as the community standard of care, and (3) the failure, through non-medical reasons on 
the defendants' part106 to provide the community standard of care to cure inmates and 
prevent the spreading of this infectious disease. 107 The non-medical reasons argued by 
the plaintiffs include: (1) the administrative convenience, (2) cost, and (3) correctional 
policies designed to ration medication to a limited number of inmates. 108 The lawsuits 
state that the Federal Bureau of Prisons, the CDC, the United States Public Health Service 
(Surgeon General), the FDA, and the United States Department ofVeteransAffairs (VA) 
have all recognized this twelve week treatment program as the new standard of care 
within the medical community for the treatment of Hepatitis C. 109 
In all three pending class action lawsuits, the various departments of corrections have 
filed similar answers raising parallel affirmative defenses. In response to the complaint 
filed by inmates, the Minnesota Department of Corrections asserts the following 
affirmative defenses in its Answer: (1) failure to state a claim under 42 U.S.C. § 1983; (2) 
101 Federal Bureau of Prisons, Clinical Guidance, Evaluation 
uu<:u,run. October, 2016. 
102 See supra note 78. 
103 Id. 
104 See Amended pg. 4, Ligons v. lvfinnesota Dept. 
Case No. 15-cv-02210-PJS-BRT (2015). 
10s Id. 
106 Defendants include not the Department of Corrections, but also name 
officials in their individual and official ""~1ao.,rnc,. 
HCV 
and medical 
107 See Chimenti v. Dept. of Corrections, No. 15-3333, 2016 U.S. Dist. LEXIS 36682 
(E.D. Pa. Mar. 21, 2015); Paszko v. O'Brien, No. l-15-cv-12298-NMG (D. Mass. June 10, 2015); 
v. Minnesota Dept. of Corrections, No. 15-cv-02210-PJS-BRT (D. Minn. filed May 1, 2015). 
108 Greg Dober, Minnesota DOC Sued Over Failure to Provide New Hepatitis C Treatment 
Protocol, Prison News (Oct. 15, 
30, 2017). 
109 See Amended at 2-3, Ligons, supra note 4; Compfa1i11t at 13, ru,zKu',l>U;uru note 4; 
Comp,laurrtat 9, Chimenti, supra note 4. 
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claims may be barred by the statute oflimitations; (3) claims may be barred by qualified 
immunity and the Eleventh Amendment; (4) sovereign immunity, official immunity, 
vicarious official immunity, statutory immunity and/or discretionary immunity; (5) such 
damages and/or injuries are the result of the plaintiff's own conduct and actions and/or 
actions of third person( s) over whom the Department of Corrections exercises no control; 
( 6) the damages were caused by risks known to or primarily assumed by the plaintiffs; 
(7) plaintiffs' damages were the result of a natural disease process, pre-existing medical 
conditions, pre-existing medical disabilities, a superseding cause, an act of nature and/ 
or the act or omission of persons over whom the Department of Corrections does not 
have control; and (8) the Department's actions or conduct was authorized by law, was 
reasonable and was taken in good faith. 110 
In her Answer, Commissioner Higgins O'Brien admits that over 1,500 patients in the 
custody of the Massachusetts Department of Correction are known to have Hepatitis 
c.rn The Massachusetts Partnership for Correctional Healthcare, LLC's Answer 
contains similar defenses to those raised by the Minnesota Department of Corrections, 
listed above. One distinct difference raised in Massachusetts Partnership's answer is 
that the defendants' actions do not rise to the level of a constitutional violation; and 
therefore, the plaintiffs cannot recover. 112 Defendants specifically note that they were 
not deliberately indifferent to the serious medical needs of the inmates. 113 
In Chimenti v. Pennsylvania Dept. of Corrections the Department of Corrections has 
filed a Motion to Dismiss based on a failure to state a claim and a Motion to Sever. The 
Department's Motion to Dismiss was granted in part and denied in part. The motion was 
granted pursuant to certain counts alleged against certain Defendants named in the suit; 
however, the Motion to Dismiss was denied in all other respects. 114 Additionally, the 
Motion to Dismiss and Sever filed by the Medical Defendants was granted in part and 
denied in part. 115 The granted portion of the motion pertained to the claims asserted in 
Count I against Defendants Andrew Dancha, Dr. John Hochberg, Dr. Nicholas Scharff, 
Dr. Thomas Lehman, and Correct Care Solutions, which count has been dismissed 
against the above referenced Defendants. 116 
110 Defendant's Minnesota Department of Corrections Roy, Paulson and Larson's Answer to 
Plaintiff's First Amended at 20-22, Ligons v. Minnesota Dept. U.S.D.C. 
(D. Minn.), Case No. 15-cv-02210-PJS-BRT (2015). 
111 Answer of Defendant Carol 
No. 1-15-cv-12298-NMG (2015). 
O'Brien, 5, Paszko O'Brien, lJ.S.D.C. (D. Mass.), Case 
for Correctional Healthcare, LLC Answer and Jury Demand to 
Plaintiff's '-·ump•1a11mat 8-9, Paszko O'Brien, U.S.D.C. (D. Mass.), Case No. l-15-cv-12298-
NMG (2015). 
113 Id. 
114 Order dated March 21, 2016, Chimenti, supra note 4. 
115 See id. that count I asserts an Amendment deliberate indifference claim 
pursuant to 42 U.S.C. § 1983 twelve of the Defendants, all six of the DOC 
Defendants: the DOC; John Wetzel, the Secretary of the DOC; Paul Noel, Chief Medical Director of 
the DOC; Oppman; Dreibelbis; and Korszniak). 
116 id. 
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A series of articles have been published bringing national attention to the issue of whether 
prison authorities have the right to deny prisoners life-saving medical care based on the 
price tag of treatment. 117 Although the price tag of the curing treatment is an issue raised 
by the inmates, the specific issue that the courts will have to answer in these class action 
suits, which will set precedent for the Department of Corrections nationwide, is whether 
the Department of Corrections is required to provide the latest standard of care to avoid 
a constitutional violation of failing to provide adequate care to inmates. 
III. JUDICIAL SOLUTION 
A. How Should The Courts Address This Matter? 
Section 1983 provides remedies for deprivations of rights established in the Constitution 
or federal laws. 118 42 U.S.C. § 1983 provides, in pertinent part: 
Every person who, under color of any statute, ordinance, regulation, custom, or usage, 
of any State ... , subjects, or causes to be subjected, any citizen of the United States or 
other person within the jurisdiction thereof to the deprivation of any rights, privileges, 
or immunities secured by the Constitution and laws, shall be liable to the party injured 
in an action at law, suit in equity, or other proper proceeding for redress ... 119 
To establish a 42 U.S.C. § 1983 claim, a plaintiff must demonstrate (1) that he has 
been deprived of a right secured by the Constitution and laws of the United States; 
and (2) that the alleged deprivation was committed by a person acting under color of 
state law. 120 
All three class action complaints allege, the Department of Corrections, through its 
officials and medical providers, have violated these prisoners' rights under the Eighth 
Amendment to be free from cruel and unusual punishment. A prisoner's treatment and 
the conditions of imprisonment are subject to EighthAmendment scrutiny. 121 However, 
courts have held that "the duty to provide a certain level of health care to incarcerated 
offenders under the Eighth Amendment is a limited one."122 "Not 'every ache and 
pain or medically recognized condition involving some discomfort can support an 
Eighth Amendment claim."'123 The United States Supreme Court has found that a 
117 See Peter Loftus, Prisoners Sue Massacfn1se1'ts 
STREET J. (June 11, 2015), 
"'"'ucuu101x, Inmates' Suit Claims Massachusetts 
Denies Prisoners Hepatitis C Drugs, MAss LIVE (June 15, 2015), 
index.ssf/2015/06/inmates __ sue_massachusselts_for.html; see also Lawsuits Ke1g-ar·drnw 
Treatment, FREE MuMIA (Sept 16, 2015), 
l/minnesota-doc-sued-over-failme-prov:ide-new-hepatitis-c-treatment-protocol. 
118 See Baker v. McCollan, 443 US. 137, 145, at 3 (1979). 




onn!Prn°nn1Pn1 School Dist, 894 F2d 1176, 1186 
lVlUl'o..Hl!lCy, 509 U.S. 25, 31 (1993). 
'/hr;•mn.,nn No. 03-2633, 2004 WL 2203585 
123 Id. (quoting Gutierrez v. Peters, 111 F.3d 1364, 1372 
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"deliberate indifference to serious medical needs of prisoners violates the [Eighth] 
Amendment because it constitutes the unnecessary and wanton infliction of pain 
contrary to contemporary standards of decency."124 Thus, a plaintiff must show both 
"deliberate indifference" and a "serious medical need."125 The first test is subjective, 
the second is objective. 126 
A plaintiff must show that the defendant knew of a substantial risk of serious harm to the 
plaintiff and still refused medical assistance. 127 The official must "both be aware of facts 
from which the inference could be drawn that a substantial risk of serious harm exists, 
and he must also draw the inference."128 
[The test for deliberate indifference] affords considerable latitude to prison medical 
authorities in the diagnosis and treatment of medical problems of inmate patients. 
Courts will 'disavow any attempt to second-guess the propriety or adequacy of a 
particular course of treatment .. . [which] remains a question of sound professional 
judgment.' Bowring v. Godwin, 551 F.2d 44, 48 (4th Cir.1977). Implicit in this 
deference to prison medical authorities is the assumption that such an informed medical 
judgment has, in fact, been made. When, however, prison authorities prevent an inmate 
from receiving recommended treatment for serious medical needs or deny access to a 
physician capable of evaluating the need for such treatment, the constitutional standard 
of Estelle has been violated. 129 
Questions of medical judgment, disagreement between an inmate and medical personnel 
regarding diagnosis and course of treatment, and mere malpractice do not constitute 
deliberate indifference. 130 However, a delay in medical treatment may constitute 
deliberate indifference. 131 A constitutional violation only occurs if the delay results in 
some "substantial harm" to the patient. 132 
In addition to "deliberate indifference," the plaintiff must also show that such 
indifference was directed to a "serious medical need."133 Because society does not 
expect that prisoners will have unqualified access to healthcare, ' a prisoner must first 
124 Helling v: Estelle, supra note 1, at 104). 
125 Estelle, supra note 1, at l 06. 
126 See Parks v. Blanchette, No. 3:09-CV-604 (VAB), 2015 WL 6755208, at* 17 (D. Conn. Nov. 
4, 2015); see also Salahuddin v. Goord, 467 F3d 263, 279-80 Cir.2006); see also v. 
Price, 996 F2d 1064, 1066-67 Cir. 1993)(quoting Miller v: Glanz, 948 F2d 1562, 1569 
Cir.1991)). 
127 Farmer v. Brennan, 511 US. 825, 834 (l 994). 
v. Delaware Cnty., No. CV 14-4833, 2015 WL 5302736, at *4 (E.D. Pa. Sept 10, 2015) 
Farmer v. Brennan, supra note 127, at 834). 
129 Gomm v. DeLand, 729 F Supp. 767, 779 (D. Utah 1990) (quoting Inmates County 
Jail v. Pierce, 612 F2d 754, 762 Cir. 1979)). 
130 See Viands v. No. L: 14CV506 GBL/MSN, 2015 WL 5277202, at *4 (E.D. Va. Sept 
8, 2015) Davis v. Lester, 156 588, 598 (WD.Va.2001)). 
131 See Smith v. Smith, 589 F3d 736, 739 Cir.2009) Estelle, supra note 1, at 104-05). 
132 Viands v. supra note 130 
133 Id Estelle, supra note 1, at 105). 
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make [a] threshold showing of serious illness or injury" to state a cognizable claim. "134 
On the other hand, courts have recently held that when deliberate indifference relates 
to medical care "[ t ]he requirement of deliberate indifference is less stringent ... than in 
other Eighth Amendment contexts because the responsibility to provide inmates with 
medical care does not generally conflict with competing penological concerns."135 
Generally, deliberate indifference to serious medical needs may be manifested in 
two ways: "when prison officials deny, delay, or intentionally interfere with medical 
treatment, or ... by the way in which prison physicians provide medical care."136 The 
Tenth Circuit has found that prison officials may be liable for an Eighth Amendment 
violation for "indifference ... manifested ... in their response to the prisoner's needs 
or by .. . intentionally denying or delaying access to medical care or intentionally 
interfering with treatment once prescribed."137 
"Serious medical needs" are those diagnosed by a physician as mandating treatment or 
those that are so obvious that even a lay person would easily recognize the necessity for 
a doctor's attention. 138 Courts have found a serious medical need "if the failure to treat 
the prisoner's condition could result in further significant injury or [if] [there] [is] the 
'unnecessary and wanton infliction of pain'" it may qualify as a serious medical need. 139 
Indications may include "[ t ]he existence of an injury that a reasonable doctor or patient 
would find important and worthy of comment or treatment; the presence of a medical 
condition that significantly affects an individual's daily activities; or the existence of 
chronic and substantial pain."140 
In addition to demonstrating that the medical need is objectively serious, the plaintiff 
must also show that the delay in the provision of medical care resulted in objectively 
"substantial harm" in order to establish an Eighth Amendment violation. 141 "The 
134 Miller v. Ramineni, 9: 14-CV-1351 (N.D. New York Feb. 29, 2016) (citing Smith v. Carpenter, 
316 F3d 178, 184 (2d Cir.2003) (quoting Hudson v. McMillian, 503 US. 1, 9 (1992)); see Wilson 
v. Prison Health Services, 406 Fed. App'x 671 (unpublished opinion) ("[P]risoners do not have a 
constitutional right to limitless medical care, free of the cost constraints under which law-abiding 
citizens receive treatment"). 
135 See Holliday v. Naku, 2009 US. Dist LEXIS 55757, at *5 (E.D. Cal. June 26, 2009) (citing 
McGuckin v. Smith, 974 F2d 1050, 1059-60 (9th Cir.1991). 
136 See Scanlan v. Tran, No. 1:15-CV-00282-LJO, 2015 WL 5178387, at *5 (ED. Cal. Sept 4, 
2015) (citing Hutchinson v. United States, 838 F2d 390, 393-94 (9th Cir.1988)); see also Smith 
v. Carpenter, 316 F3d 178, 183-84 (2d Cir.2003) (quoting Salahuddin, supra note 126, at 279-
80) (describing that when assessing the objective prong, the Court must determine (a) "whether 
the prisoner was actually deprived of adequate medical care," and (b) "whether the inadequacy in 
medical care is sufficiently serious" to constitute a constitutional violation"). 
137 See Brooks v. Oba, No. 13-CV-02894-CBS, 2015 WL 4036189, at *4 (D. Colo. July 1, 2015) 
(quoting Estate of Booker v. Gomez, 745 F3d 405, 429 (10th Cir.2014)). 
138 See id. at 1202 (quoting Ramos v. Lamm, 639 F2d 559, 575 (10th Cir.1980)). 
139 See McGuckin v. Smith, 974 F2d 1050, 1059 W11 Cir.1991) (quoting Estelle, supra note 1, at 
104). 
140 Scanlan, supra note 136, at *4 (citing Wood v. Housewright, 900 F2d 1332, 1337-41 (9th 
Cir.1990)). 
141 See Webb v. Hamidullah, 281 Fed. App'x. 159, 166-67 (4th Cir.2008) (unpublished decision); 
see also Shabazz v. Prison Health Servs., No. 3:10cvl90, 2011WL2489661, at *5-6 (E.D.Va. Aug. 
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substantial harm requirement may be satisfied by lifelong handicap, permanent loss, or 
considerable pain."142 
Courts have recently upheld the notion that Hepatitis meets the requirement of being an 
objectively serious medical condition. 143 Therefore, the main hurdle that plaintiffs will 
face in these recent suits is establishing the subjective test of deliberate indifference. 
The Sixth Circuit has recently held that for a corporation to act with the requisite level 
of subjective intent, it must do so through its policies and customs. 144 This notion was 
directly applied in the context of a correction facility. The court found that "[p ]laintiff 
must allege that the employees acted in accordance with some official policy or custom 
of [the Department of Corrections], or that [the Department of Corrections] encouraged 
the specific misconduct or in some way directly participated in it."145 Although the case 
was dismissed for failure to state a claim, it was filed in the context of an inmate alleging 
an Eighth Amendment violation for the failure of a correctional facility to provide the 
drug Sovaldi to treat the inmate's Hepatitis C. 
The most relevant finding of the Sixth Circuit Court is as follows: 146 
[t]he question is not whether a prisoner is receiving the medication or treatment of his 
choosing, or whether he is receiving the best health care available for his condition. 
Instead, the inquiry for Eighth Amendment purposes is whether the course of treatment 
he is receiving is "so grossly incompetent, inadequate, or excessive as to shock the 
conscience or to be intolerable to fundamental faimess."147 The relevant inquiry 
to determine whether the Defendant provided grossly inadequate care is "whether a 
reasonable doctor ... could have concluded his actions were lawful."148 
Although the representatives in the class actions lawsuits have set forth advanced stages 
of the virus, recent case law may foreclose relief to those who cannot show such advanced 
stages. 149 The Tennessee Department of Corrections recently prevailed over an inmate's 
claim alleging that he was denied medical care, even though the facility was aware 
that he tested positive for the Hepatitis C. 150 The plaintiff in that case was diagnosed 
with Hepatitis C, Genotype 1.151 The court focused on the primary indicator of whether 
treatment of Hepatitis C is warranted as being the regular and consistent monitoring 
9,2011). 
142 Shabazz. supra note 141, at *6. 
143 Garrison v. Corr. Corp. of Am., No. 1:15 CV 177, 20!5 U.S. Dist. LEXIS 87309, at *3 (N.D. 
Ohio 6, 2015). 
144 See Monell v~ Dept. of Soc. Servs .. 436 US. 658, 691 ( 1978). 





1\.fonell, supra note 144, at 690-91). 
149 Parks, supra note 126, at 306 that these are 
150 Shabazzv. Schofield, No. 3:13-0091, 2015 US. Dist. LEXIS 113082, at *1212 (M.D. Tenn. 
Aug. 26, 2015). 
151 Id.at *2. 
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of liver enzyme levels, specifically the SGOT/AST and SGPT/ALT levels. 152 Both of 
these tests indicate specific liver enzyme production or a lack thereof. 153 The Tennessee 
Department of Corrections implemented a policy where all inmates in custody, who have 
been diagnosed with Hepatitis C, are monitored for increased liver enzyme levels on a 
regular basis. 154 They are also assessed by physical exam to evaluate for any symptoms 
at regularly scheduled intervals. 155 
The plaintiff's medical records show that lab work has been conducted at least thirteen 
times since January, 2013. 156 The latest lab work revealed that the plaintiff's liver was 
functioning normal, and in the same range as individuals who did not have Hepatitis 
C. 157 Additionally, the plaintiff's liver enzyme levels indicated that his liver was not in 
active cirrhosis. 158 Since the plaintiff's Hepatitis C was stable and he was not in any way 
in an acute phase, the court found that the Department's general policy of monitoring 
enzyme levels at least every three months for all inmates diagnosed with Hepatitis C was 
sufficient, because the policy was consistent with generally accepted medical practices, 
regardless of whether the patient was incarcerated or not. 159 
The Garrison case limited relief available to an inmate and did not require the Tennessee 
Department of Corrections to provide the latest drug breakthrough to all inmates, unless 
they could show the medical standard of care for the level of advanced virus they have. 
This holding is consistent with Graham v. Wright where a prisoner complained of delay 
in providing treatment for Hepatitis C. 160 In Graham the court held that the objective 
element of deliberate indifference standard must be satisfied by "harm that resulted 
from the delay."161 
Further, the CDC has found that not everyone requires treatment or can benefit from 
treatment. 162 This determination should be made by after being checked by a doctor 
experienced in treating chronic Hepatitis C. 163 He or she can determine the most 
appropriate medical care. 164 Decisions about starting treatment are based on many 
factors, such as the type of virus, the condition of the liver, and other health conditions. 165 
152 Id. 
153 id. 
154 Shabazz, supra note 141 at *2. 
155 See id. 
156 See id. 
157 See id. 
158 See id. 
159 See id. 
160 Graham v. No. 01 Civ. 9613 (NRB), 2004 U.S. Dist. LEXIS 15738, at *5 (SDN.Y 
Aug. 10, 2004). 
161 Id. at *7. 
162 See Hepaiitis C and Baby Boomers 
(Jan. 27, 2015), 
163 See id. 
164 id. 
165 See id.; see also Watson v. No. 08-CV-00960(A)(M), 2011 U.S. Dist. LEXIS 
30874, at *10 (W.D. N.Y. Jan. 11, 2011) that many courts in this circuit have held that 
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In expanding beyond a determination of each individual on a case-by-case basis, the 
issue of adequate medical care versus the community standard of medical care has 
directly been addressed across the jurisdictions. In October 2015, the United States 
District Court for the Central District of California specifically found that "the Eighth 
Amendment does not require optimal medical care or even medical care that comports 
with the community standard of medical care."166 This same concept has been upheld in 
the District of Nevada by finding "[o]nly where the prison's chosen course of treatment 
is 'medically unacceptable under the circumstances' are the officials' medical choices 
constitutionally infirm."167 
Additional case law from the Eastern District of Wisconsin168 has held: 
[t]o establish deliberate indifference, the prisoner must demonstrate "that the treatment 
he received was 'blatantly inappropriate,"' id. (quoting Greeno v. Daley, 414 F.3d 645, 
654 (7th Cir.2005)); or, stated another way, that the treatment decision "represents 
so significant a departure from accepted professional standards or practices that it 
calls into question whether the [medical professional] was actually exercising his 
professional judgment," id. (citing Roe v. Elyea, 631 F.3d 843, 857 (7th Cir.2011) 
and Sain v. Wood, 512 F.3d 886, 895 (7th Cir.2008)); Gayton, 593 F.3d at 622-23. 
(Emphasis added). 
However, because there is more than one treatment option for Hepatitis C, which may 
be determined based on a number of factors presented by each individual, New York 
courts have held that determinations specifically pertaining to the treatment of Hepatitis 
C and compliance with "[Department of Correctional Services] Guidelines, reflect 
medical judgments, not 'deliberate indifference' under the Eighth Amendment."169 
Additionally, the Third Circuit recently held that in making the determination of 
prescribing certain drugs or treatment, the Eighth Amendment does not completely bar 
medical professionals and healthcare administrators from considering cost as a factor 
when evaluating treatment options. 170 
"determinations as to whether 1o treat pursuant to [Department of Correctional 
Services] Guidelines, reflect not 'deliberate indifference' under the 
Amendment"). 
166 Dancy v. Johnson, No. EDCV 15-1463-AG (JEM), 2015 US. Dist LEXIS 142034, at *5 (C.D. 
Cal. Oct 19, 2015). 
167 Pattison v. Nevada, No. 3:14-CV-00020-MMD-VPC, 2015 US. Dist. LEXIS 127697, at *3 (D. 
Nev. Sept 23, 2015). 
168 Locke v. Ritter, No. 14-CV-1143-JPS, 2015 US. Dist LEXIS 131504, at *6 (E.D. Wis. Sept 29, 
2015) added). 
169 Watson, note 165, at * 10. 
170 Viera v. Williams, No. 1:13-CV-02424, 2015 US. Dist LEXIS 136693, at *5 (M.D. Pa. Oct 7, 
2015) Winslow v. Prison Health Servs., 406 F App'x 671, 674 Cir.2011). 
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IV.AN ANALYSIS OF THE WYOMING STATE POLICY AND 
POTENTIAL IMPLICATIONS 
This section will provide an illustration of the Wyoming Department of Corrections 
health policy as it relates to Hepatitis C, and is intended only to serve as an practical 
example. The Wyoming Department of Corrections currently has a policy and 
procedure that provides for health screens and a health appraisal of all inmates. Policy 
4.305(11) provides: 
A. Health Screens. It is the policy of the WDOC that all inmates receive an intake 
health screen performed by health-trained or qualified health care personnel 
upon arrival to WDOC facilities and that all findings of these health screens 
are recorded on a screening form approved by the health authority. 
B. Health Appraisal. It is the policy of the WDOC that all inmates (excluding 
intra-system transfers) receive a comprehensive health appraisal, unless 
there is documented evidence of a health appraisal within the previous 
ninety (90) days. 171 
Under this policy, health screens shall be performed within the first few hours of arrival. 172 
The screenings should include an inquiry into any past history of serious infectious 
communicable illnesses and medications, current illnesses and health problems which 
specifically include communicable diseases, encompassing Hepatitis C. 173 Under the 
requirements for the health appraisal, the facility staff and the qualified health care 
professionals shall perform laboratory and/or diagnostic tests to detect communicable 
diseases within seven days of arrival. 174 
The Wyoming Department of Corrections has even gone one step further and 
implemented an Exposure Control Plan to protect staff members and inmates from 
blood-borne pathogens. 175 The plan identifies and addresses the following criteria: 
"individuals and types of contact, precautions, protection, handling, housekeeping, 
proper disposal and training of individuals." 176 This plan is specifically designed to meet 
federal, state and local regulations and guidelines with an emphasis on the Wyoming 
Occupational Safety and Health Rules and Regulation as they apply to correctional 
facilities. 177 This policy further requires that the contracted medical service providers 
create and implement procedures to comply with this policy, OSHA standards and 
the Department of Correction's standards. Lastly, the Department of Corrections has 
172 Jd.at3. 
173 Id. 
174 Id.at 6. 
2 29,2016), 
175 \VYO:VlING DEPARTMENT OF CORRECTIONS, POLICY AND PROCEDURE #3.210 \'-''""'""'""i J, 2016), 
see also \VYOMlNG DEPARTMENT OF CORRECTIONS, POLICY AND PROCEDURE #4.303, 3 (Nov. 15, 
2015), see also WYOM!"JG DEPARTMENT OF CORRECTIONS, 
POLICY AND PROCEDURE, supra note 16 l, at 2. 
177 Id.at 2. 
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implemented a policy addressing the management of Hepatitis C, including procedures 
for when and where inmates are to be tested/screened and under what conditions inmates 
are to be separated from the general population. 178 The only concerning implication is 
the testing of inmates. Under Policy and Procedure # 4.312(B)(5), inmates shall be 
tested if they show symptoms associated with the disease; whereas the testing for HIV 
is mandatory during the initial screening of all inmates. 179 
CONCLUSION 
Hepatitis C poses a substantial risk not only to prisoners, but also to the general 
population. Statistics show that at least "95% of all state prisoners will be released from 
prison at some point."180 However, just as any medical professional would examine 
each patient diagnosed with cancer individually, the same concept should be applied to 
those diagnosed with Hepatitis C. Because the disease affects each person differently, 
and advances at different intervals in every person diagnosed, medical care should be 
provided to inmates just as it would be to the general community population. In the 
event that the newly approved curing treatment is found to be the accepted professional 
standard or practice of care for all stages of the disease, then such treatment would be 
required to be provided to not only inmates diagnosed with Hepatitis C, but also to all 
individuals contracted with Hepatitis C. However, at this time, this is not the current 
practice or professional standard. Because a treating physician evaluates numerous 
factors to determine the appropriate method of treatment, including the cost of such 
treatment, the advanced stage of the disease, and each patient on a case-by case bases; 
the current class actions should not succeed in seeking to have the latest development in 
drugs for treating Hepatitis C made available to every prison inmate. Finally, because the 
latest recognized standard of care drugs are not required to provide "adequate" medical 
treatment to satisfy the Eight Amendment, absent a diagnosis of an advanced stage of 
Hepatitis C, the states' Department of Corrections should not be mandated to provide 
this costly treatment to inmates, and the class actions should not prevail. 
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